Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors
- PMID: 18480741
Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors
Abstract
Aim: The aim of the present study was to prospectively evaluate the add value provided by [(111)In]DTPA-octreotide single-photon emission computed tomography/computed tomography (Octreo-SPECT/CT) with respect to [(111)In]DTPA-octreotide SPECT (Octreo-SPECT) in terms of diagnostic accuracy and localization of neuroendocrine tumors (NETs).
Methods: Eighty-one consecutive patients with known or suspected NET underwent [(111)In]DTPA-octreotide scintigraphy using an integrated SPECT/low-energy-CT system (Infinia & Hawkeye; GE Medical Systems, Milwaukee, WI, USA). SPECT and fused SPECT/CT images were interpreted separately and a lesion-by-lesion analysis was performed with regard to classification (probability of NET graded on a 5-point scale) and localization of each abnormal focal tracer uptake. A subgroup analysis, distinguishing between abdominal and thoracic lesions, and a patient-by-patient analysis for likelihood of NET in each patient was also performed. Standard of reference for confirming presence or absence of NET was either histopathology or clinical/imaging follow-up data. The value of SPECT/CT imaging was assessed by ROC analysis and McNemar test.
Results: A final diagnosis of NET was achieved in 43 out of 81 patients and a total of 169 areas (138 NET and 31 benign/physiological) with focal tracer uptake were included in the final lesion-by-lesion analysis. SPECT/CT imaging led to a significantly higher proportion of patients (75/81=92.6% vs 64/81=79%) and lesions (163/169=96.4% vs 138/169=81.1%) correctly classified vs SPECT alone. ROC analysis confirmed that Octreo-SPECT/CT performed significantly better than Octreo-SPECT for the detection of NET on both patient- and lesion-based analysis, improving especially evaluation of abnormal tracer uptake in the abdomen. Moreover, Octreo-SPECT/CT accurately localized 160/169 (94.7%) lesions, significantly higher than SPECT alone (77/169= 45.6%).
Conclusions: Octreo-SPECT/CT allows more accurate detection and localization of NETs than simple Octreo-SPECT, with major benefits for lesions located in the abdomen.
Similar articles
-
Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.Nucl Med Commun. 2015 Mar;36(3):251-9. doi: 10.1097/MNM.0000000000000239. Nucl Med Commun. 2015. PMID: 25369750
-
Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours.Radiol Med. 2008 Oct;113(7):1056-67. doi: 10.1007/s11547-008-0319-9. Epub 2008 Sep 16. Radiol Med. 2008. PMID: 18797822 English, Italian.
-
Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms.Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):835-43. doi: 10.1007/s00259-003-1160-y. Epub 2003 Apr 8. Eur J Nucl Med Mol Imaging. 2003. PMID: 12682789
-
Radio-guided surgery in neuroendocrine tumors.J Surg Oncol. 2007 Sep 15;96(4):309-15. doi: 10.1002/jso.20868. J Surg Oncol. 2007. PMID: 17726664 Review.
-
Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours.Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S186-9. Ital J Gastroenterol Hepatol. 1999. PMID: 10604127 Review.
Cited by
-
Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors.Clinics (Sao Paulo). 2012;67 Suppl 1(Suppl 1):109-12. doi: 10.6061/clinics/2012(sup01)18. Clinics (Sao Paulo). 2012. PMID: 22584714 Free PMC article. Review.
-
[Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].Radiologe. 2020 May;60(5):413-420. doi: 10.1007/s00117-020-00652-y. Radiologe. 2020. PMID: 32052116 Review. German.
-
Artificial intelligence in single photon emission computed tomography (SPECT) imaging: a narrative review.Ann Transl Med. 2021 May;9(9):820. doi: 10.21037/atm-20-5988. Ann Transl Med. 2021. PMID: 34268433 Free PMC article. Review.
-
Somatostatin receptor SPECT.Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S41-51. doi: 10.1007/s00259-011-2019-2. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388628 Review.
-
3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.EJNMMI Phys. 2017 Dec;4(1):6. doi: 10.1186/s40658-016-0172-1. Epub 2017 Jan 18. EJNMMI Phys. 2017. PMID: 28101733 Free PMC article.